Cytomegalovirus pp65 Antibody (B051M) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NB110-68199
Key Product Details
Species Reactivity
Cytomegalovirus, Virus
Applications
Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # B051M
Format
BSA Free
Concentration
1.3 mg/ml
Product Specifications
Immunogen
CMV Lysate
Specificity
Specific for pp65 of CMV. Functions in pp65 antigenemia assay (indirect IFA). (B051M)
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Cytomegalovirus pp65 Antibody (B051M) - BSA Free
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
1:10-1:500
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
0.01 M Phosphate Buffered Saline, pH 7.2. Product contains no stabilizing proteins.
Format
BSA Free
Preservative
0.1% Sodium Azide
Concentration
1.3 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4°C.
Background: Cytomegalovirus pp65
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
64 kDa lower matrix phosphoprotein, 65 kDa lower matrix phosphoprotein, CMV, CMV 65 kDa lower matrix phosphoprotein, CMV pp65, CMV pp65 IE, CMV tegument protein UL83, cytomegalovirus, Cytomegalovirus 65 kDa lower matrix phosphoprotein, Cytomegalovirus pp65, Cytomegalovirus tegument protein UL83, GP64, PP64, PP65, Tegument protein UL 83, Tegument protein UL83, UL 83, UL83
Additional Cytomegalovirus pp65 Products
Product Documents for Cytomegalovirus pp65 Antibody (B051M) - BSA Free
Product Specific Notices for Cytomegalovirus pp65 Antibody (B051M) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...